These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34742474)

  • 21. Clinicopathological features of kidney injury in patients receiving immune checkpoint inhibitors (ICPi) combined with anti-vascular endothelial growth factor (anti-VEGF) therapy.
    Jin S; Shen Z; Li J; Liu X; Zhu Q; Li F; Shi Y; Lin P; Xu X; Chen X; Geng X; Ding X; Liu H
    J Clin Pathol; 2024 Jun; 77(7):471-477. PubMed ID: 38242556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB.
    O'Malley G; Lee HJ; Parekh S; Galsky MD; Smith CB; Friedlander P; Yanagisawa RT; Gallagher EJ
    Endocr Pract; 2017 Oct; 23(10):1223-1231. PubMed ID: 29045188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer.
    Muir CA; Menzies AM; Clifton-Bligh R; Tsang VHM
    Thyroid; 2020 Oct; 30(10):1458-1469. PubMed ID: 32264785
    [No Abstract]   [Full Text] [Related]  

  • 24. Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors.
    Lima Ferreira J; Costa C; Marques B; Castro S; Victor M; Oliveira J; Santos AP; Sampaio IL; Duarte H; Marques AP; Torres I
    Cancer Immunol Immunother; 2021 Feb; 70(2):299-309. PubMed ID: 32712715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.
    Osorio JC; Ni A; Chaft JE; Pollina R; Kasler MK; Stephens D; Rodriguez C; Cambridge L; Rizvi H; Wolchok JD; Merghoub T; Rudin CM; Fish S; Hellmann MD
    Ann Oncol; 2017 Mar; 28(3):583-589. PubMed ID: 27998967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
    Guaraldi F; La Selva R; Samà MT; D'Angelo V; Gori D; Fava P; Fierro MT; Savoia P; Arvat E
    J Endocrinol Invest; 2018 May; 41(5):549-556. PubMed ID: 29043574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
    Iyer PC; Cabanillas ME; Waguespack SG; Hu MI; Thosani S; Lavis VR; Busaidy NL; Subudhi SK; Diab A; Dadu R
    Thyroid; 2018 Oct; 28(10):1243-1251. PubMed ID: 30132401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Graves' Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review).
    Peiffert M; Cugnet-Anceau C; Dalle S; Chikh K; Assaad S; Disse E; Raverot G; Borson-Chazot F; Abeillon-du Payrat J
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33920721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Characters and Influence Factors of Immune Checkpoint Inhibitor-related Thyroid Dysfunction.
    Zhang Q; Jiao X; Lai X
    J Clin Endocrinol Metab; 2023 Oct; 108(11):2916-2923. PubMed ID: 37183427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune checkpoint blockade PD-1 therapy for primary liver cancer: incidence and influencing factors of thyroid dysfunction.
    Wu H; Xiong F; Bao X; Lu J
    Infect Agent Cancer; 2022 Dec; 17(1):64. PubMed ID: 36581947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. So slow, so fast, a case of nivolumab-induced hypothyroidism with subsequent rhabdomyolysis.
    Abushalha K; Abulaimoun S; Silberstein PT
    Immunotherapy; 2020 Jun; 12(9):625-628. PubMed ID: 32418490
    [No Abstract]   [Full Text] [Related]  

  • 32. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey.
    Vanderpump MP; Tunbridge WM; French JM; Appleton D; Bates D; Clark F; Grimley Evans J; Hasan DM; Rodgers H; Tunbridge F
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):55-68. PubMed ID: 7641412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A; Kottschade L; Ryder M
    Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
    [No Abstract]   [Full Text] [Related]  

  • 34. Analysis of Factors Associated with Thyroid Dysfunction: A Hospital Based Study.
    Risal P; Adhikari B; Shrestha R; Manandhar S; Bhatt RD; Hada M
    Kathmandu Univ Med J (KUMJ); 2019; 17(66):88-92. PubMed ID: 32632053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors.
    Inaba H; Ariyasu H; Iwakura H; Kurimoto C; Takeshima K; Morita S; Furuta H; Hotomi M; Akamizu T
    Endocr J; 2021 Feb; 68(2):231-241. PubMed ID: 33012745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and clinical characteristics of thyroid abnormalities in cancer patients treated with immune checkpoint inhibitors.
    Cuenca D; Rodríguez-Meléndez E; Aguilar-Soto M; Sánchez-Rodríguez A; Íñiguez-Ariza N; Olivares-Beltrán G; Gerson-Cwilich R; Mercado M
    Gac Med Mex; 2021; 157(3):293-297. PubMed ID: 34667315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
    Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
    Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum concentrations of tumour necrosis factor-alpha (TNF-alpha) and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function.
    Díez JJ; Hernanz A; Medina S; Bayón C; Iglesias P
    Clin Endocrinol (Oxf); 2002 Oct; 57(4):515-21. PubMed ID: 12354134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database.
    Hasegawa S; Ikesue H; Nakao S; Shimada K; Mukai R; Tanaka M; Matsumoto K; Inoue M; Satake R; Yoshida Y; Goto F; Hashida T; Nakamura M
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1279-1294. PubMed ID: 32869941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prevalence of thyroid dysfunction in patients with type 2 diabetes mellitus].
    Centeno Maxzud M; Gómez Rasjido L; Fregenal M; Arias Calafiore F; Córdoba Lanus M; D'Urso M; Luciardi H
    Medicina (B Aires); 2016; 76(6):355-358. PubMed ID: 27959843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.